Oncology
Merck’s Keytruda approved by EC for gastric cancer
August 30, 2023Research and Development EC, Merck, Oncology, gastric cancer, keytruda
Merck (known as MSD outside of the US and Canada) has announced the approval of its gastric cancer treatment, Keytruda, …
FDA gives Orphan Drug Designation to Faron Pharmaceuticals’ Bexmarilimab
August 29, 2023Research and Development FDA, Faron, ODD, Oncology, leukemia
Faron Pharmaceuticals announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its …
Takeda and ImmunoGen collaborate for development and commercialisation of Elahere in Japan
August 29, 2023Sales and Marketing Elahere, Immunogen, Oncology, Takeda
ImmunoGen has announced that it has entered into an exclusive collaboration with Takeda Pharmaceutical Company for the development and commercialisation …
Janssen submits sNDA to FDA for full approval of Balversa
August 29, 2023Research and Development Balversa, FDA, Janssen, Oncology
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the submission of a supplemental New Drug Application (sNDA) to …
Lynparza granted approval to treat prostate cancer in Japan
August 25, 2023Research and Development Merck, Oncology, astra zeneca, prostate cancer
AstraZeneca and Merck (known as MSD outside the US and Canada) have received approval from the Japanese Ministry of Health, …
FDA grants ODD to NXC-201 as multiple myeloma treatment
August 24, 2023Medical Communications FDA, Nexcella, ODD, Oncology, multiple myeloma
Nexcella has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to NXC-201 for …
Daiichi Sankyo’s Enhertu approved in Japan as treatment for metastatic NSCLC
August 23, 2023Medical Communications Daiichi Sankyo, Enhertu, Japan's MHLW, NSCLC, Oncology, trastuzumab deruxtecan
Daiichi Sankyo has announced that Enhertu (trastuzumab deruxtecan) has been approved in Japan for the treatment of adult patients with …
Eli Lilly shares topline results from LIBRETTO-531 trial for Retevmo
August 23, 2023Research and Development Eli Lilly, Oncology, Retevmo, clinical trial, slpercatinib, thyroid cancer
Eli Lilly has announced topline results from the LIBRETTO-531 study assessing Retevmo (selpercatinib) as an initial treatment for patients with …
Merck announces phase 3 LITESPARK-005 trial met primary endpoint
August 22, 2023Research and Development Merck, Oncology, Welireg, belzutifan, clinical trial, renal cell carcinoma
Merck (known as MSD outside of the US and Canada) has shared topline results from its phase 3 LITESPARK-005 trial, …
FDA grants accelerated approval to Pfizer’s Elrexfio
August 15, 2023Medical Communications Elrexfio, FDA, Oncology, Pfizer, accelerated approval
Pfizer has that the US Food and Drug Administration (FDA) has granted accelerated approval to Elrexfio (elranatamab-bcmm) for the treatment …
FDA grants orphan drug designation to Genprex’s Reqorsa
August 15, 2023Medical Communications FDA, ODD, Oncology, Reqorsa
Gene therapy company Genprex has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) …
NICE shares draft guidance for AI’s use in radiotherapy treatment planning
August 14, 2023Research and Development AI, Draft Guidance, NICE, Oncology, radiotherapy
The National Institute for Health and Care Excellence (NICE) has shared draft guidance surrounding nine artificial intelligence (AI) technologies which …
FDA approved Janssen’s Akeega for prostate cancer treatment
August 14, 2023Research and Development Akeega, FDA, J&J, Janssen, Oncology, prostate cancer
The Janssen Pharmaceutical companies of Johnson & Johnson have announced that the US Food and Drug Administration (FDA) has approved …
Zumutor’s cancer drug trial cleared by FDA
August 14, 2023Research and Development Cancer, Oncology, clinical trial, pharmaceutical
On 11 August 2023, the biopharmaceutical company Zumutor Biologics announced that the trial of its ZM008 drug for cancer had …
FDA approves Talvey for the treatment of heavily pretreated multiple myeloma
August 11, 2023Medical Communications FDA, J&J, Janssen, Oncology, Talvey, multiple myeloma
The Janssen Pharmaceutical companies of Johnson & Johnson has announced that the US Food and Drug Administration (FDA) has granted …
Latest content
FibroFind appoints Lee Borthwick as CEO
